Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management
Description
The discussion focuses on two complex cases of autoimmune connective tissue diseases (CTDs), particularly highlighting the diagnosis and management of scleromyxedema and silicone-induced granulomas. The first case features a 47-year-old man presenting with distinctive waxy monomorphic papules and skin induration consistent with scleromyxedema, a rare condition linked to IgG Lambda paraproteinemia. Clinically, these individuals exhibit multiple systemic manifestations, including myositis and potential organ involvement. Treatment with intravenous immunoglobulin (IVIG) has shown promising effectiveness despite an absence of change in paraproteinemia levels, indicating a need for long-term management. The second case involves a 39-year-old male referred for sclerosing skin plaques alongside hypercalcemia and kidney issues, with a history of anabolic steroid and silicone injection. Biopsy indicated silicone-induced granulomas contributing to both cutaneous and systemic complications. The take-home message emphasizes awareness of silicone-related cutaneous reactions and the importance of thorough patient history in CTD diagnoses, particularly when dealing with individuals who may have undergone unconventional cosmetic procedures.
View moreConclusions
- Scleromyxedema is identified as a rare sclerotic mucin deposition disorder with significant clinical manifestations.
- A strong association was found between scleromyxedema and IgG lambda paraproteinemia.
- The absence of thyroid disease is crucial in diagnosing scleromyxedema.
- Systemic manifestations of scleromyxedema can be severe and potentially life-threatening, involving myositis and neurologic complications.
- IVIG is established as the first-line treatment for cutaneous and systemic manifestations of scleromyxedema, but long-term management is necessary to prevent relapses.
- Continuous IVIG treatment improves patient outcomes and should be maintained for effective disease control.
- Cases of silicone-induced fibrosis can cause atypical sclerosing presentations and should be considered in differential diagnoses, especially in patients with cosmetic procedure history.
- Hypercalcemia and renal failure may arise from granulomatous reactions secondary to silicone injections.
- Elston, D. M. (2017). Path: Elston's Dermatopathology. 2nd Ed.
- PMID: 28370513. High-dose IVIG for scleromyxedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. 2017.